Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization

Contributed by: ACCESSWIRE

Logo

Tags

Biotechnology

Clairvoyant Therapeutics

Company Update

More Like This

Clairvoyant Surpasses 50 Per Cent Randomization in its Phase 2b Psilocybin Therapy Trial for Alcohol Use Disorder

PR Newswire associated0

B.More Collaborator, Dr. Michael Bogenschutz, Awarded NIAAA Grant for Psilocybin in Alcohol Use Disorder Trial at NYU and Silver Hill Hospital

Trial of new psychedelic drug seeks patients with Treatment Resistant Depression

National call for volunteers to test ground-breaking psychedelic treatments for mental health conditions

PR Newswire associated0

B.More Collaborator, Dr. Michael Bogenschutz, Awarded $15 Million NIDA Grant for Landmark Psilocybin Study in Opioid Use Disorder

Strong and durable effects 4 months after 2 doses (Graphic: Business Wire)

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

First Patient Dosed in Beckley Psytech’s International Phase IIb Study of BPL-003, a Novel Synthetic Intranasal Formulation of 5-MeO-DMT, for Treatment Resistant Depression (TRD)